Fortress Biotech, Inc. reported a 14% increase in total net revenue, reaching $18.7 million for the second quarter of 2026. This positive trend reflects ongoing momentum in partnered programs and enhancing Shareholder value through strategic initiatives.
Key Highlights
- Total net Revenue grew 14% to $18.7 million in Q2 2026.
- Crystalys Therapeutics secured $130 million in Series B financing for dotinurad development.
- Journey Medical expanded access to Emrosi®, reaching over 150 million commercial lives.
Fortress Biotech, Inc. reported total net revenue of $18.7 million for the second quarter of 2026, marking a 14% increase compared to the same quarter in 2025. This growth illustrates the company’s successful strategy in advancing its product portfolio and achieving significant financial milestones. The notable revenue rise can be attributed to partnerships and Royalty streams from products such as ZYCUBO® and UNLOXCYT™, presenting a strong foundation for continued operations and strategic investments.
This upward trajectory in revenue is particularly vital as the company positions itself in a dynamic biopharmaceutical environment.
Q2 Revenue Insights
Fortress Biotech's total net revenue reached $18.7 million for the quarter ended June 30, 2026, a 14% increase year-over-year. The revenue expansion is driven primarily by partnerships, including strengthened relationships fostering clinical advancements. One highlight includes Urica Therapeutics’ stake in Crystalys Therapeutics, which recently announced a $130 million Series B financing to propel the development of dotinurad, a next-generation gout treatment.
Fortress has a 3% royalty agreement on future net sales of dotinurad, suggesting a potential for significant revenue contributions from this asset in the future. This favorable positioning aligns with the company's long-term strategy aimed at enhancing shareholder value through a diversified revenue stream.
Corporate Highlights
Recent activities of Fortress Biotech include Journey Medical's successful expansion in the market for Emrosi®. The drug has achieved a third major GPO contract, allowing access to over 150 million commercial lives, which bolsters its market footprint considerably. This expansion improves the likelihood of higher sales volumes and greater revenue from the product.
The company reaffirmed that its diversified portfolio positions it well for ongoing development and commercialization efforts, further enhancing its ability to Capitalize on emerging market opportunities. The growth in payer access demonstrates significant strategic progress and strengthens Fortress Biotech’s Business endeavors in commercializing innovative therapies.
Strategic Developments
Lindsay A. Rosenwald, M.D. Chairman and CEO of Fortress Biotech, noted consistent clinical advancements across partnered programs, including a successful report by AstraZeneca regarding anselamimab. The reported 62% improvement in survival among specific patient groups and a 71% reduction in hospitalizations highlight the potential impact of their collaborative clinical research efforts. These outcomes may lead to key regulatory submissions and open new market opportunities for Fortress, particularly as it aims to scale its developmental pipeline.
The emphasis on clinical breakthroughs underscores the company’s commitment to advancing treatments and maximizing returns for its shareholders.
Future Catalysts
As Fortress Biotech continues its momentum into the second half of 2026, the company is well positioned to Leverage favorable cash balance boosted by the $205 million PRV sale from earlier in the year. This Liquidity enhances its capacity to advance pipeline projects and explore new business development opportunities. Observers will be particularly attentive to future developments surrounding the regulatory submissions for anselamimab and the ongoing phase trials for dotinurad, which could influence the company's revenue and growth trajectory significantly.






Please wait processing your request...